PL370175A1 - Kompozycja farmaceutyczna zawierająca glitazon i kwas 4-oksobutanowy oraz jej zastosowanie w leczeniu cukrzycy - Google Patents

Kompozycja farmaceutyczna zawierająca glitazon i kwas 4-oksobutanowy oraz jej zastosowanie w leczeniu cukrzycy

Info

Publication number: PL370175A1
Authority: PL; Poland
Prior art keywords: glitazone; pharmaceutical composition; treating diabetes; oxobutanoic acid; oxobutanoic
Prior art date: 2002-01-11

Application number

PL02370175A

Other languages

English (en)

Inventor

Gerard Moinet

Dominique Marais

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-11

Filing date

2002-12-16

Publication date

2005-05-16

2002-12-16 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2005-05-16 Publication of PL370175A1 publication Critical patent/PL370175A1/pl

Links

UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 title 2
NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL02370175A 2002-01-11 2002-12-16 Kompozycja farmaceutyczna zawierająca glitazon i kwas 4-oksobutanowy oraz jej zastosowanie w leczeniu cukrzycy PL370175A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0200335A FR2834640B1 (fr)	2002-01-11	2002-01-11	Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete

Publications (1)

Publication Number	Publication Date
PL370175A1 true PL370175A1 (pl)	2005-05-16

Family

ID=8871257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02370175A PL370175A1 (pl)	2002-01-11	2002-12-16	Kompozycja farmaceutyczna zawierająca glitazon i kwas 4-oksobutanowy oraz jej zastosowanie w leczeniu cukrzycy

Country Status (16)

Country	Link
US (1)	US20050085489A1 (pl)
EP (1)	EP1463503A1 (pl)
JP (1)	JP2005516963A (pl)
KR (1)	KR20040078109A (pl)
CN (1)	CN1599608A (pl)
AR (1)	AR038287A1 (pl)
AU (1)	AU2002361421A1 (pl)
BR (1)	BR0215498A (pl)
CA (1)	CA2473043A1 (pl)
FR (1)	FR2834640B1 (pl)
HU (1)	HUP0402645A2 (pl)
MX (1)	MXPA04006675A (pl)
PL (1)	PL370175A1 (pl)
RU (1)	RU2004124523A (pl)
WO (1)	WO2003057216A1 (pl)
ZA (1)	ZA200406329B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014158916A1 (en)	2013-03-14	2014-10-02	Dart Neuroscience, Llc	Substituted naphthyridine and quinoline compounds as mao inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863915A (en) *	1996-05-15	1999-01-26	Bayer Corporation	Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
FR2752422B1 (fr) *	1996-08-16	1998-11-06	Lipha	Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
GB9922710D0 (en) *	1999-09-24	1999-11-24	Bayer Ag	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis

2002
- 2002-01-11 FR FR0200335A patent/FR2834640B1/fr not_active Expired - Fee Related
- 2002-12-16 CA CA002473043A patent/CA2473043A1/en not_active Abandoned
- 2002-12-16 BR BR0215498-6A patent/BR0215498A/pt not_active IP Right Cessation
- 2002-12-16 JP JP2003557574A patent/JP2005516963A/ja active Pending
- 2002-12-16 AU AU2002361421A patent/AU2002361421A1/en not_active Abandoned
- 2002-12-16 HU HU0402645A patent/HUP0402645A2/hu unknown
- 2002-12-16 EP EP02796640A patent/EP1463503A1/en not_active Withdrawn
- 2002-12-16 KR KR10-2004-7008823A patent/KR20040078109A/ko not_active Withdrawn
- 2002-12-16 RU RU2004124523/15A patent/RU2004124523A/ru not_active Application Discontinuation
- 2002-12-16 WO PCT/EP2002/014311 patent/WO2003057216A1/en not_active Ceased
- 2002-12-16 MX MXPA04006675A patent/MXPA04006675A/es unknown
- 2002-12-16 US US10/501,069 patent/US20050085489A1/en not_active Abandoned
- 2002-12-16 CN CNA028244060A patent/CN1599608A/zh active Pending
- 2002-12-16 PL PL02370175A patent/PL370175A1/pl unknown
2003
- 2003-01-10 AR ARP030100058A patent/AR038287A1/es unknown
2004
- 2004-08-10 ZA ZA200406329A patent/ZA200406329B/en unknown

Also Published As

Publication number	Publication date
KR20040078109A (ko)	2004-09-08
US20050085489A1 (en)	2005-04-21
MXPA04006675A (es)	2004-10-04
HUP0402645A2 (hu)	2005-07-28
JP2005516963A (ja)	2005-06-09
RU2004124523A (ru)	2005-06-10
ZA200406329B (en)	2005-09-20
CN1599608A (zh)	2005-03-23
BR0215498A (pt)	2004-12-28
WO2003057216A1 (en)	2003-07-17
AU2002361421A1 (en)	2003-07-24
CA2473043A1 (en)	2003-07-17
EP1463503A1 (en)	2004-10-06
AR038287A1 (es)	2005-01-12
FR2834640B1 (fr)	2004-09-24
FR2834640A1 (fr)	2003-07-18

Legal Events

Date	Code	Title	Description
2010-03-31	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
TWI347313B (en)	2011-08-21	Novel substituted phenoxyacetic acids,pharmaceutical composition comprising them,and use thereof
GB2394894B (en)	2005-08-31	New use for pharmaceutical composition
IL165977A (en)	2010-12-30	Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
SI1572707T1 (sl)	2006-08-31	Novi aromatski fluorglikozidni derivati, farmacevtski proizvodi, ki vsebujejo te spojine, in njihova uporaba
EP1433032A4 (en)	2010-09-15	PORTABLE DOSING CALCULATOR
EP1405859A4 (en)	2008-01-23	NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF
AU2003291103A8 (en)	2004-06-15	Pharmaceutical composition
IL164547A0 (en)	2005-12-18	Pharmaceutical composition
SI1467724T1 (sl)	2006-08-31	Orodisperzibilen farmacevtski sestavek z agomelatinom
IL165012A0 (en)	2005-12-18	(S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
IL165878A0 (en)	2006-01-15	Pharmaceutical composition
PL394600A1 (pl)	2011-07-18	Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
HUP0401612A3 (en)	2006-04-28	Pharmaceutical composition suitable for treating diabetes
IL165242A0 (en)	2005-12-18	Treatment for diabetes
AU2003252182A8 (en)	2004-02-16	Therapeutic treatment for the metabolic syndrome and type 2 diabetes
EP1559703A4 (en)	2006-05-24	NATURAL COMPOUND FOR THE TREATMENT OF DIABETES, THEIR PREPARATION AND USE
HRP20040691A2 (en)	2004-12-31	2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug
PL370175A1 (pl)	2005-05-16	Kompozycja farmaceutyczna zawierająca glitazon i kwas 4-oksobutanowy oraz jej zastosowanie w leczeniu cukrzycy
HUP0600455A2 (en)	2006-09-28	Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
IL164901A0 (en)	2005-12-18	Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
IL182125A0 (en)	2007-07-24	Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof
SI1448181T1 (sl)	2006-10-31	Farmacevtski sestavek, ki obsega kombinacijo metformina in 4-oksobutanojske kisline, ter njegova uporaba za zdravljenje diabetesa
AU2003252701A1 (en)	2004-02-16	Medicinal composition for treating thrombopenia
GB0217703D0 (en)	2002-09-11	Pharmaceutical composition
AU2002350563A1 (en)	2003-05-26	Pharmaceutical composition comprising a glitazone and a thiazolidinedione derivative, and use thereof for treating diabetes